Insulet
PODD
#1150
Rank
$16.20 B
Marketcap
$231.11
Share price
-0.54%
Change (1 day)
76.74%
Change (1 year)
Categories
Insulet Corporation is an American company that develops and sells medical devices used for the administration of insulin.

P/E ratio for Insulet (PODD)

P/E ratio as of October 2024 (TTM): 134

According to Insulet's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 134.494. At the end of 2022 the company had a P/E ratio of > 1000.

P/E ratio history for Insulet from 2007 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2022> 1000263.54%
2021> 1000-50.22%
2020> 1000144.34%
2019951-28.06%
2018> 1000-981.33%
2017-150103.03%
2016-73.9154.03%
2015-29.1-41.28%
2014-49.510.8%
2013-44.7127.5%
2012-19.62.26%
2011-19.290.9%
2010-10.171.27%
2009-5.88161.86%
2008-2.24147.98%
2007-0.9050

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
-87.4-165.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-10.1-107.50%๐Ÿ‡บ๐Ÿ‡ธ USA
73.3-45.53%๐Ÿ‡บ๐Ÿ‡ธ USA
11.3-91.57%๐Ÿ‡บ๐Ÿ‡ธ USA
38.1-71.67%๐Ÿ‡บ๐Ÿ‡ธ USA
33.3-75.26%๐Ÿ‡ฎ๐Ÿ‡ช Ireland
145 7.56%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.